247 related articles for article (PubMed ID: 27327958)
1. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
2. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
Chen ZY; Dong Q; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
[TBL] [Abstract][Full Text] [Related]
3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
6. Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC).
Boegemann M; Schrader AJ; Krabbe LM; Herrmann E
Curr Cancer Drug Targets; 2015; 15(3):243-55. PubMed ID: 25654638
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
8. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
Batra A; Winquist E
Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
[TBL] [Abstract][Full Text] [Related]
9. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
[TBL] [Abstract][Full Text] [Related]
10. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
12. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
13. [Methods for androgen receptor splice variant-7 detection: Advances in studies].
Li K; Fan GR; Chen CH; Wang ZP
Zhonghua Nan Ke Xue; 2019 Nov; 25(11):1031-1035. PubMed ID: 32233239
[TBL] [Abstract][Full Text] [Related]
14. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
Kim W; Ryan CJ
Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
[TBL] [Abstract][Full Text] [Related]
15. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
16. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS
Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
18. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR
J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435
[TBL] [Abstract][Full Text] [Related]
19. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]